Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

BACKGROUND: Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age. Safe, effective vaccines are needed to protect this population, facilitate in-person learning and socializ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Frenck, Robert W., Klein, Nicola P., Kitchin, Nicholas, Gurtman, Alejandra, Absalon, Judith, Lockhart, Stephen, Perez, John L., Walter, Emmanuel B., Senders, Shelly, Bailey, Ruth, Swanson, Kena A., Ma, Hua, Xu, Xia, Koury, Kenneth, Kalina, Warren V., Cooper, David, Jennings, Timothy, Brandon, Donald M., Thomas, Stephen J., Türeci, Özlem, Tresnan, Dina B., Mather, Susan, Dormitzer, Philip R., Şahin, Uğur, Jansen, Kathrin U., Gruber, William C.
Formato: Artigo
Idioma:Inglês
Publicado em: Massachusetts Medical Society 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8174030/
https://ncbi.nlm.nih.gov/pubmed/34043894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2107456
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados